Yesterday, I had the pleasure of sitting down with Howard Federoff to discuss the exciting progress Kenai Therapeutics is making in advancing iPSC-based programs for treating Parkinson’s Disease (full interview coming soon!).
We touched on the wide range of neurological diseases that could be promising targets for cell therapies in the future, such as Alzheimer’s Disease, which is already being explored by companies like NKGen Biotech, Inc.. This made me wonder about the current distribution of research of cell therapies products across neurological disorders – my findings of which I have outlined below.
As the figure shows, Multiple Sclerosis and Parkinson’s Disease are receiving the most attention. However, given how early this field is, I anticipate significant growth into other disease areas in the coming years—particularly in conditions with shared pathologies like demyelination and neurodegeneration, where stem cell-derived products could offer substantial benefits versus current treatment options.
This December, we’ll be featuring presentations from leading drug developers and academics working on these and other disease areas. If you'd like to join the first-ever gathering of these experts for focused networking and clinical data presentations, register for the Cell Therapy for Neurological Disorders
Summit (December 11-13, 2024, San Diego).
Find more details here: https://ter.li/sr01sk
#CellTherapy #NeurologicalDisorders #iPSC #ParkinsonsDisease #AlzheimersDisease #MultipleSclerosis #Neurodegeneration #StemCells #RegenerativeMedicine #Biotech
